TARGETED THERAPY IN COMPREHENSIVE MANAGEMENT OF METASTATIC COLON CANCER

Abstract

In recent years there has been strong progress in the treatment of metastatic colorectal cancer (mCRC) patients. The gain of the median of the overall survival (mOS) rate was more than doubled due to the introduction in the clinical practice of new compounds, the work of a multidisciplinary team, the timely registration of the disease progress, prescription of combined chemotherapy in the second line. The article presents the immediate and long-term results of a comparative study carried out on the basis of Oncology Centers, 122 mCRC patients were included, most of these patients - 87(71,3%) had surgery firstly, after that all patients were treated with standard chemotherapy FOLFOX-4 in the first-line treatment and FOLFIRI in the second line treatment, two groups of patients in the first and second lines of treatment received a combination of chemotherapy and targeted agents (bevacizumab, cetuximab), depending on the biological properties of the tumor (RAS-gene mutation status). The following results: metastatic progression-free survival (mPFS) for FOLFOX-4 group accounted for 12.0(±1.2) months; FOLFOX-4 + Bevacizumab - 20.3(±1.2) months, FOLFOX-4 + cetuximab - 22.0(± 2.0) months; mPFS for second-line therapy for FOLFIRI + bevacizumab group amounted to 24.0(± 3.1) months, FOLFIRI + cetuximab 22.5(±2.5) months, FOLFIRI-1 8.0(±2.4) months, FOLFIRI-2 6.4(±2.6) months; mOS for FOLFOX-4 group was 49.5(±2.5) months; FOLFOX-4 + Bevacizumab - 45.8(±2.1) months; FOLFOX-4 + cetuximab - 37.4(± 2.0) months; mOS for second-line therapy for FOLFIRI + bevacizumab group was 37.8(± 2.1) months, FOLFIRI + cetuximab - 31.5(± 2.3) months, FOLFIRI-1 - 26.3(± 1.8) months, FOLFIRI-2 - 26.2(± 1.9) months. The adverse events during the treatment of patients are reported.

Keywords

metastatic colorectal cancer / the first and second-line chemotherapy of metastatic colorectal cancer / targeted therapy of metastatic colorectal cancer / bevacizumab / cetuximab

References

[1] Grothey A., Sugrue M.M., Purdie D.M., Dong W., Sargent D., Hedrick E., Kozloff M. Bevacizumab beyond first progression in associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol. 2008; 26(33): 5326-34. DOI: 10.1200/JCO.2008.16.3212.

[2] Van Cutsem E., Rivera F., Berry S. et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann. Oncol. 2009; 20(11): 1842-7. DOI:10.1093/annonc/mdp233.

[3] Cohn A.L., Beckaii-Saab T., Bendell J.C. Clinical outcomes in bevacizumab (BV) - treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on beyond progression (BBP). J. Clin. Oncol. 2010: abstr 3596.

[4] Weitz J., Koch M., Debus J. et al. Colorectal cancer. Lancet. 2005; 365: 153-65.

[5] Falcone A. Treatment goals: What should we be aiming for? Alfredo Falcone - 2016.-WCGIC-mCRC-symp 03.

[6] Douillard J., Cunningham D., Roth A. et al. Irinotecan combined with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentrerandomised trial. Lancet. 2000; 355: 1041-7.

[7] De Gramont A., Figure A., Seymour M. et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000; 18: 2938-47.

[8] Tournigand C., André T., Achille E. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 2004; 22: 229-37.

[9] Grothey A., Sargent D., Goldberg R.et al. Survival of patients withadvanced colorectal cancer improves with the availability of fluorouracil leucovorin,irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 2004; 22; 1209-14.

[10] Douillard, J.Y., Siena S, Peeters M. et al. Impact of early tumor shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur. J. Cancer. 2015; 51: 1231-42.

[11] Van Cutsem E., Cervantes A., Adam R. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology. 2016: 1-38. doi:10.1093/annonc/mdw235

[12] Venook, A. Niedzwiecki, D., Lenz, H.J. CALGB/SWOG 80405 Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J. Clin. Oncol. 2014. - 32 - 5s (ESMO - 2014. - abstract 5010)

[13] Heinemann V.,von Weikersthal L-F., Decker T. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 14: 1470-2045.

[14] Fedyanin M.Yu., Tryakin A.A., Tyulyandin S.A. First-line treatment of patients with metastatic inoperable colorectal cancer. Onkologicheskaya koloproktologiya. 2014; (4): 12-5. (in Russian) / Федянин, М.Ю. Трякин, А.А., Тюляндин, С.А. Первая линия лечения больных метастатическим неоперабельным раком толстой кишки. Онкологическая колопроктология. 2014; (4): 12-5.

[15] Artamonova E.V., Manzyuk L.V. Optimization second-line treatment of metastatic colorectal cancer: new opportunities for targeted therapy. Consilium Medicum. 2016; 1. http://con-med.ru/magazines/contemporary/contemporary-01-2016/optimizatsiya_vtoroy_linii_lecheniya_metastaticheskogo_kolorektalnogo_raka_novye_vozmozhnosti_target/ (in Russian) /Артамонова Е.В., Манзюк Л.В. Оптимизация второй линии лечения метастатического колоректального рака: новые возможности таргетной терапии. Consilium Medicum. 2016; 1. Режим доступа: http://con-med.ru/magazines/contemporary/contemporary-01-2016/optimizatsiya_vtoroy_linii_lecheniya_metastaticheskogo_kolorektalnogo_raka_novye_vozmozhnosti_target/

RIGHTS & PERMISSIONS

Eco-Vector